Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1Recruiting 1Active not recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, B-Cell, Marginal Zone 2Multiple Myeloma 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Rituximab 23Cyclophosphamide 15ibrutinib 14acalabrutinib 13CT-P10 10venetoclax 8Lenalidomide 8Bendamustine Hydrochloride 8fludarabine 7Cytarabine 6fludarabine phosphate 5zanubrutinib 4obinutuzumab 4Peripheral Blood Stem Cell Transplantation 4Methotrexate 4pirtobrutinib 3Whole-Body Irradiation 3Tacrolimus 3Mycophenolic Acid 3Melphalan 3Etoposide 3palbociclib 2merphos 2dexamethasone acetate 2dexamethasone 21-phosphate 2brexucabtagene autoleucel 2auricularum 2Vincristine 2Stem Cell Transplantation 2Specimen Handling 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Lymphoma, Mantle-Cell × Hyaluronoglucosaminidase × Clear all
NCT03267433 2026-05-05

Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission

Eastern Cooperative Oncology Group

Phase 3 Active not recruiting
689 enrolled
Lymphoid

Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡